Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb-Apr;15(1-2):62-9.
doi: 10.1016/j.drup.2012.02.001. Epub 2012 Mar 11.

Drug resistance: still a daunting challenge to the successful treatment of AML

Brian C Shaffer  1 , Jean-Pierre Gillet, Chirayu Patel, Maria R Baer, Susan E Bates, Michael M Gottesman
Affiliations
Review

Drug resistance: still a daunting challenge to the successful treatment of AML

Brian C Shaffer et al. Drug Resist Updat. 2012 Feb-Apr.

Abstract

Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related proteins, are plasma membrane transporters able to efflux a variety of substrates from the cell cytoplasm, including chemotherapeutic agents. The discovery of ABCB1 made available a potential target for pharmacologic down-regulation of efflux-mediated chemotherapy resistance. In patients with acute myeloid leukemia (AML), a neoplasm characterized by proliferation of poorly differentiated myeloid progenitor cells, leukemic cells often express ABCB1 at high levels, which may lead to the development of resistance to chemotherapy. Thus, AML seemed to be a likely cancer for which the addition of drug efflux inhibitors to the chemotherapeutic regimen would improve outcomes in patients. Despite this rational hypothesis, the majority of clinical trials evaluating this strategy have failed to reach a positive endpoint, most recently the Eastern Cooperative Oncology Group E3999 trial. Here we review data suggesting the importance of ABCB1 in AML, address the failure of clinical trials to support a therapeutic strategy aimed at modulating ABCB1-mediated resistance, and consider the type of research that should be conducted in this field going forward.

PubMed Disclaimer

Conflict of interest statement

Authorship

Contribution: B.C.S., J.-P.G., C.P., M.R.B., S.E.B., and M.M.G. all contributed to writing the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. Blood. 2002;100:4594–4601. - PubMed
    1. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–361. - PubMed
    1. Apáti A, Orbán TI, Varga N, Németh A, Schamberger A, Krizsik V, et al. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim. Biophys. Acta. 2008;1778:2700–2709. - PubMed
    1. Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen DW, et al. Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol. Blood Marrow Tr. 2010;16:1649–1657. - PubMed
    1. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and leukemia group B study 9720. Blood. 2002;100:1224–1232. - PubMed

Publication types

MeSH terms

Substances

-